Case Report
This case report discusses daily treatment with silymarin and highlights moderate efficacy and a good safety profile in the management of non-alcoholic steatohepatitis (NASH) and liver function with no side-effects, supporting silymarin as a promising supplemental intervention that can normalize liver activity in non-alcoholic fatty liver disease and NASH.
Original Research
This article analyzes the data collected from the T-Coach patient support programme and evaluates the effect of the programme in terms of treatment satisfaction, adherence and effect on disease knowledge. 6-month results are present here.
Original Research
Recent recommendations by the American Society of Health System Pharmacists and Infectious Disease Society of America have provided guidance regarding vancomycin dosing and monitoring in serious infections; however, trough monitoring for uncomplicated acute bacterial skin and skin structure infections (ABSSSI) were not addressed. Vancomycin use appears to lead to a low incidence of acute kidney injury with short durations and a low trough goal. Nevertheless, clinical studies have found no difference in clinical outcomes for ABSSSI regardless of vancomycin level. Therefore, it can be posed whether trough monitoring is necessary in this patient population. The objective of this study was to determine if vancomycin treatment duration differs for patients with ABSSSI with a sub-therapeutic vancomycin trough (ST; <10 mg/L) compared with therapeutic trough (TT; ≥10 mg/L).
Case Report
This case report focuses on a patient planning surgery due to lumbar stenosis who was recommended for silymarin treatment, as increased liver enzyme levels were incidentally
found during examination.
Review
This article aims to review the current knowledge on deucravacitinib, a new oral small molecule that selectively inhibits tyrosine kinase 2 (TYK2), for the treatment of psoriatic arthritis.
